\
&
Contact us
This was 1 year ago
Locationvirtual
ProgrammesThe Marie Skłodowska-Curie Actions (MSCA) Doctoral Networks (DN) Coordinators’ Information Day is organised by the European Commission and the European Research Executive Agency (REA) and is targeting the consortia funded under the MSCA DN 2023 call. Τhe aim is to inform MSCA DN coordinators and beneficiaries about the main rules and procedures governing DNs and management and procedural aspects of the project lifecycle.
To prepare for this session, pre-recorded presentations on recruitment, finances, audit, reporting, grant agreement obligations, Industrial Doctorates and Joint Doctorates, open science and communication/dissemination and exploitation will be made available one month before the event. Participants will have the opportunity to raise questions through Slido, as of two weeks before and during the event.
All information related to this event can be found on the research and innovation community platform on the European Commission website.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.